{"id":59829,"date":"2026-03-18T13:42:24","date_gmt":"2026-03-18T05:42:24","guid":{"rendered":"https:\/\/flcube.com\/?p=59829"},"modified":"2026-03-18T13:42:25","modified_gmt":"2026-03-18T05:42:25","slug":"bio-heart-bio-expands-iberis-rdn-registration-to-thailand-worlds-only-dual-access-renal-denervation-system","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59829","title":{"rendered":"Bio-heart Bio Expands Iberis RDN Registration to Thailand \u2013 World&#8217;s Only Dual\u2011Access Renal Denervation System"},"content":{"rendered":"\n<p><strong>Shanghai Bio-heart Biological Technology Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2185:HKG\">HKG: 2185<\/a>) announced <strong>Thailand regulatory registration<\/strong> of its <strong>Iberis multi\u2011electrode renal radiofrequency denervation (RDN) system<\/strong>, extending the commercial footprint of the <strong>world&#8217;s only RDN device approved for both transradial access (TRA) and transfemoral access (TFA)<\/strong> in a key Southeast Asian hypertension intervention market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Iberis multi\u2011electrode renal radiofrequency denervation (RDN) system<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185)<\/td><\/tr><tr><td><strong>New Registration<\/strong><\/td><td>Thailand<\/td><\/tr><tr><td><strong>Prior Approvals<\/strong><\/td><td>European Union, Indonesia, and other markets<\/td><\/tr><tr><td><strong>Unique Differentiation<\/strong><\/td><td>World&#8217;s only RDN system approved for <strong>both TRA and TFA<\/strong> access routes<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-clinical-advantage\">Product Profile &amp; Clinical Advantage<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology:<\/strong> <strong>Multi\u2011electrode renal radiofrequency denervation (RDN)<\/strong> \u2013 catheter\u2011based sympathetic nerve ablation for hypertension management<\/li>\n\n\n\n<li><strong>Access Innovation:<\/strong> <strong>Dual\u2011route approval<\/strong> \u2013 <strong>transradial access (TRA)<\/strong> + <strong>transfemoral access (TFA)<\/strong><\/li>\n\n\n\n<li><strong>TRA Clinical Benefits:<\/strong><\/li>\n\n\n\n<li><strong>Safer:<\/strong> Reduced bleeding and vascular complication risk vs. femoral approach<\/li>\n\n\n\n<li><strong>More effective:<\/strong> Equivalent or superior renal nerve ablation outcomes<\/li>\n\n\n\n<li><strong>More cost\u2011effective:<\/strong> Shorter procedure time, reduced hospital stay, faster patient ambulation<\/li>\n\n\n\n<li><strong>Global Regulatory Status:<\/strong> CE\u2011marked (EU); approved Indonesia; now Thailand\u2011registered<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercialization-structure\">Commercialization Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Bio-heart Position<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Direct Markets<\/strong><\/td><td>China, Thailand, select territories<\/td><td>Maintains control in core Asia markets<\/td><\/tr><tr><td><strong>Licensing Partner<\/strong><\/td><td><strong>Biosensors International Group, Ltd.<\/strong> (Singapore\u2011based)<\/td><td>Established cardiovascular device commercialization infrastructure<\/td><\/tr><tr><td><strong>Partner Territories<\/strong><\/td><td>European Union, Asia\u2011Pacific (ex\u2011direct markets), Latin America (LATAM)<\/td><td>Accelerates global penetration without direct sales force investment<\/td><\/tr><tr><td><strong>Revenue Model<\/strong><\/td><td>Licensing fees + royalties on partner sales<\/td><td>Capital\u2011efficient international expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hypertension Intervention Landscape:<\/strong> Resistant hypertension affects ~10\u201115% of global hypertensive population (estimated 100+ million patients); RDN represents catheter\u2011based alternative for patients failing pharmacotherapy, with market potential exceeding <strong>US$2 billion annually<\/strong> by 2030.<\/li>\n\n\n\n<li><strong>Southeast Asia Market Dynamics:<\/strong> Thailand registration provides ASEAN market anchor; estimated 4\u20115 million resistant hypertension patients in Southeast Asia with limited access to advanced interventional therapies; Iberis TRA advantage aligns with regional cost\u2011consciousness and outpatient procedure preferences.<\/li>\n\n\n\n<li><strong>TRA Differentiation Moat:<\/strong> Competitor RDN systems (Medtronic&#8217;s Symplicity, Recor&#8217;s Paradise) are TFA\u2011only; Iberis&#8217;s dual\u2011access approval creates procedural flexibility that may drive physician preference and hospital formulary adoption, particularly in markets where radial access is standard for coronary interventions.<\/li>\n\n\n\n<li><strong>Biosensors Partnership Leverage:<\/strong> Singapore\u2011based partner&#8217;s established EU and LATAM distribution accelerates regulatory submissions in Brazil, Mexico, and additional ASEAN markets; royalty revenue potential from partner territories estimated at <strong>US$15\u201125 million annually<\/strong> by 2028 assuming 5\u20118% market share in licensed regions.<\/li>\n\n\n\n<li><strong>Pipeline Synergies:<\/strong> Iberis platform validation supports Bio\u2011heart&#8217;s broader renal denervation portfolio including next\u2011generation electrode configurations and potential hypertension\u2011diabetes comorbidity indications.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding market penetration expectations, partnership revenue projections, and regulatory expansion timelines for the Iberis RDN system. Actual results may differ due to risks including competitive dynamics, reimbursement policy developments, and physician adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031701795_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026031701795_c.\"><\/object><a id=\"wp-block-file--media-f5825f0c-acda-460d-be7d-8cfad0edeff4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031701795_c.pdf\">2026031701795_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031701795_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f5825f0c-acda-460d-be7d-8cfad0edeff4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced Thailand regulatory registration of its Iberis&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59833,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[2607,2606,15],"class_list":["post-59829","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-bio-heart-biological-technology","tag-hkg-2185","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bio-heart Bio Expands Iberis RDN Registration to Thailand \u2013 World&#039;s Only Dual\u2011Access Renal Denervation System - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced Thailand regulatory registration of its Iberis multi\u2011electrode renal radiofrequency denervation (RDN) system, extending the commercial footprint of the world&#039;s only RDN device approved for both transradial access (TRA) and transfemoral access (TFA) in a key Southeast Asian hypertension intervention market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59829\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-heart Bio Expands Iberis RDN Registration to Thailand \u2013 World&#039;s Only Dual\u2011Access Renal Denervation System\" \/>\n<meta property=\"og:description\" content=\"Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced Thailand regulatory registration of its Iberis multi\u2011electrode renal radiofrequency denervation (RDN) system, extending the commercial footprint of the world&#039;s only RDN device approved for both transradial access (TRA) and transfemoral access (TFA) in a key Southeast Asian hypertension intervention market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59829\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T05:42:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-18T05:42:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1803.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59829#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59829\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-heart Bio Expands Iberis RDN Registration to Thailand \u2013 World&#8217;s Only Dual\u2011Access Renal Denervation System\",\"datePublished\":\"2026-03-18T05:42:24+00:00\",\"dateModified\":\"2026-03-18T05:42:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59829\"},\"wordCount\":479,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59829#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1803.webp\",\"keywords\":[\"Bio-heart Biological Technology\",\"HKG: 2185\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59829#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59829\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59829\",\"name\":\"Bio-heart Bio Expands Iberis RDN Registration to Thailand \u2013 World's Only Dual\u2011Access Renal Denervation System - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59829#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59829#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1803.webp\",\"datePublished\":\"2026-03-18T05:42:24+00:00\",\"dateModified\":\"2026-03-18T05:42:25+00:00\",\"description\":\"Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced Thailand regulatory registration of its Iberis multi\u2011electrode renal radiofrequency denervation (RDN) system, extending the commercial footprint of the world's only RDN device approved for both transradial access (TRA) and transfemoral access (TFA) in a key Southeast Asian hypertension intervention market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59829#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59829\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59829#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1803.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1803.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bio-heart Bio Expands Iberis RDN Registration to Thailand \u2013 World's Only Dual\u2011Access Renal Denervation System\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59829#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-heart Bio Expands Iberis RDN Registration to Thailand \u2013 World&#8217;s Only Dual\u2011Access Renal Denervation System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-heart Bio Expands Iberis RDN Registration to Thailand \u2013 World's Only Dual\u2011Access Renal Denervation System - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced Thailand regulatory registration of its Iberis multi\u2011electrode renal radiofrequency denervation (RDN) system, extending the commercial footprint of the world's only RDN device approved for both transradial access (TRA) and transfemoral access (TFA) in a key Southeast Asian hypertension intervention market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59829","og_locale":"en_US","og_type":"article","og_title":"Bio-heart Bio Expands Iberis RDN Registration to Thailand \u2013 World's Only Dual\u2011Access Renal Denervation System","og_description":"Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced Thailand regulatory registration of its Iberis multi\u2011electrode renal radiofrequency denervation (RDN) system, extending the commercial footprint of the world's only RDN device approved for both transradial access (TRA) and transfemoral access (TFA) in a key Southeast Asian hypertension intervention market.","og_url":"https:\/\/flcube.com\/?p=59829","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-18T05:42:24+00:00","article_modified_time":"2026-03-18T05:42:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1803.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59829#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59829"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-heart Bio Expands Iberis RDN Registration to Thailand \u2013 World&#8217;s Only Dual\u2011Access Renal Denervation System","datePublished":"2026-03-18T05:42:24+00:00","dateModified":"2026-03-18T05:42:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59829"},"wordCount":479,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59829#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1803.webp","keywords":["Bio-heart Biological Technology","HKG: 2185","Product approvals"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59829#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59829","url":"https:\/\/flcube.com\/?p=59829","name":"Bio-heart Bio Expands Iberis RDN Registration to Thailand \u2013 World's Only Dual\u2011Access Renal Denervation System - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59829#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59829#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1803.webp","datePublished":"2026-03-18T05:42:24+00:00","dateModified":"2026-03-18T05:42:25+00:00","description":"Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced Thailand regulatory registration of its Iberis multi\u2011electrode renal radiofrequency denervation (RDN) system, extending the commercial footprint of the world's only RDN device approved for both transradial access (TRA) and transfemoral access (TFA) in a key Southeast Asian hypertension intervention market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59829#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59829"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59829#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1803.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1803.webp","width":1080,"height":608,"caption":"Bio-heart Bio Expands Iberis RDN Registration to Thailand \u2013 World's Only Dual\u2011Access Renal Denervation System"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59829#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-heart Bio Expands Iberis RDN Registration to Thailand \u2013 World&#8217;s Only Dual\u2011Access Renal Denervation System"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1803.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59829"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59829\/revisions"}],"predecessor-version":[{"id":59834,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59829\/revisions\/59834"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59833"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}